Table 4.

Number and percentage of patients using each healthcare resource during 2 L treatment

Resource, n (%)a	Australia (N = 34)	Canada (N = 100)	Italy (N = 84)	UK (N = 62)	Overall (N = 280)
Hospitalization/inpatient stay	11 (32.4%)	30 (30.0%)	14 (16.7%)	20 (32.3%)	75 (26.8%)
ICU stay	-	2 (2.0%)	-	-	2 (0.7%)
Emergency room visit	3 (8.8%)	19 (19.0%)	2 (2.4%)	7 (11.3%)	31 (11.1%)
Outpatient (visit for follow-up)	21 (61.8%)	27 (27.0%)	51 (60.7%)	50 (80.6%)	149 (53.2%)
Concomitant medication	30 (88.2%)	91 (91.0%)	84 (100.0%)	60 (96.8%)	265 (94.6%)
Laboratory tests	27 (79.4%)	95 (95.0%)	78 (92.9%)	61 (98.4%)	261 (93.2%)
Blood cell count	27 (79.4%)	94 (94.0%)	78 (92.9%)	61 (98.4%)	260 (92.9%)
Biochemistry test	27 (79.4%)	92 (92.0%)	78 (92.9%)	61 (98.4%)	258 (92.1%)
Liver function test	27 (79.4%)	92 (92.0%)	78 (92.9%)	57 (91.9%)	254 (90.7%)
Renal function test	27 (79.4%)	94 (94.0%)	77 (91.7%)	56 (90.3%)	254 (90.7%)
Blood pressure reading	26 (76.5%)	53 (53.0%)	58 (69.0%)	49 (79.0%)	186 (66.4%)
Electrocardiogram	7 (20.6%)	18 (18.0%)	21 (25.0%)	14 (22.6%)	60 (21.4%)
Imaging tests	26 (76.5%)	78 (78.0%)	37 (44.0%)	56 (90.3%)	197 (70.4%)
X-ray	11 (32.4%)	44 (44.0%)	17 (20.2%)	10 (16.1%)	82 (29.3%)
Ultrasound	8 (23.5%)	24 (24.0%)	5 (6.0%)	9 (14.5%)	46 (16.4%)
CT	25 (73.5%)	60 (60.0%)	27 (32.1%)	54 (87.1%)	166 (59.3%)
MRI scan	1 (2.9%)	5 (5.0%)	1 (1.2%)	2 (3.2%)	9 (3.2%)
PET scan	-	1 (1.0%)	-	1 (1.6%)	2 (0.7%)
Fluorodeoxyglucose-PET-CT scan	5 (14.7%)	2 (2.0%)	3 (3.6%)	1 (1.6%)	11 (3.9%)
Endoscopy	2 (5.9%)	7 (7.0%)	2 (2.4%)	5 (8.1%)	16 (5.7%)
Colonoscopy	-	1 (1.0%)	1 (1.2%)	-	2 (0.7%)

^a number and percentage of patients for whom the resource has been used; denominator is the total number of patients

CT Computed tomography, ICU intensive care unit, MRI Magnetic resonance imaging, PET Positron emission tomography